Image 1. Inactivation of a DNA repair gene called FANCM enhances the formation of DNA damage and chromosomal instability induced by a PARP inhibitor, leading to massive cancer cell death. A research ...
A woman says her family is trying to raise the £2,000-a-month costs in Guernsey for her grandmother's "last option" cancer ...
TAMPA, Fla. — Ovarian cancer, often diagnosed at an advanced stage, presents significant treatment challenges because patients tend to develop resistance to conventional therapies quickly. Despite ...
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...
Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly ...
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already broadest-in-class U.S. label in prostate cancer. Following an FDA approval in 2023 that ...
Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results